Top of page

SGN35-032: A phase 2 trial of brentuximab vedotin plus chemotherapy in people with peripheral T-cell lymphoma

This trial is testing brentuximab vedotin plus chemotherapy in people who have just been diagnosed with certain types of peripheral T-cell lymphoma.


Trial aim and background

The aim of this trial is to find out how safe and effective brentuximab vedotin combined with chemotherapy is for people with certain types of peripheral T-cell lymphoma who haven’t had any previous treatment.

Everyone who takes part in this trial is treated with brentuximab vedotin combined with CHP chemotherapy (cyclophosphamide, doxorubicin [or hydroxydaunorubicin] and prednisolone).

Brentuximab vedotin is an antibody-drug conjugate: an antibody joined to a strong anti-cancer drug. The antibody sticks to a protein called CD30 on lymphoma cells and carries the drug directly to them. It is already available to treat some types of lymphoma that have come back or not responded after previous treatment.

Cyclophosphamide and doxorubicin are chemotherapy drugs that are commonly used to treat lymphoma. Prednisolone is a steroid.


Who can enter

Adults with the following types of lymphoma who have not yet received any treatment may be eligible for this trial:


Locations

  • The Beatson West of Scotland Cancer Centre, Glasgow
  • Oxford University Hospitals, Headington
  • University College London Hospitals NHS Foundation Trust, London
  • The Royal Marsden Hospital, London
  • Imperial College Healthcare NHS Trust, London
  • Christie Hospital NHS Foundation Trust, Manchester
  • The Royal Marsden Hospital, Sutton

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT04569032.

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.